Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
HUMA Stock Forecast 2026-2027
$1.38
Current Price
$306.39M
Market Cap
Buy 4
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to HUMA Price Targets
+117.4%
To High Target of $3.00
+44.9%
To Median Target of $2.00
-27.5%
To Low Target of $1.00
HUMA Price Momentum
-0.7%
1 Week Change
+30.2%
1 Month Change
-46.1%
1 Year Change
+43.8%
Year-to-Date Change
-51.4%
From 52W High of $2.84
+152.3%
From 52W Low of $0.55
📊 TOP ANALYST CALLS
Did HUMA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Humacyte is one of their latest high-conviction picks.
Latest HUMA Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, HUMA has a bullish consensus with a median price target of $2.00 (ranging from $1.00 to $3.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $1.38, the median forecast implies a 44.9% upside. This outlook is supported by 4 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Swayampakula Ramakanth at HC Wainwright & Co., projecting a 117.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HUMA Analyst Ratings
4
Buy
1
Hold
0
Sell
HUMA Price Target Range
Low
$1.00
Average
$2.00
High
$3.00
Current: $1.38
Latest HUMA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HUMA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 1, 2026 | Benchmark | Bruce D. Jackson | Speculative Buy | Maintains | $2.00 |
| May 26, 2026 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $3.00 |
| May 14, 2026 | TD Cowen | Buy | Maintains | $N/A | |
| May 13, 2026 | BTIG | Buy | Maintains | $N/A | |
| Apr 28, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Apr 28, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Apr 24, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Apr 21, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Apr 8, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Mar 31, 2026 | Benchmark | Speculative Buy | Downgrade | $N/A | |
| Mar 30, 2026 | Piper Sandler | Neutral | Maintains | $N/A | |
| Mar 30, 2026 | TD Cowen | Buy | Maintains | $N/A | |
| Mar 27, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Mar 27, 2026 | BTIG | Buy | Maintains | $N/A | |
| Mar 19, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Mar 17, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Feb 19, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Feb 10, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Feb 9, 2026 | BTIG | Ryan Zimmerman | Buy | Reiterates | $6.00 |
| Feb 9, 2026 | D. Boral Capital | Buy | Maintains | $N/A |
Humacyte, Inc. (HUMA) Competitors
The following stocks are similar to Humacyte based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Humacyte, Inc. (HUMA) Financial Data
Humacyte, Inc. has a market capitalization of $306.39M with a P/E ratio of -5.3x. The company generates $2.02M in trailing twelve-month revenue with a -376.1% profit margin.
Revenue growth is -4.3% quarter-over-quarter, while maintaining an operating margin of -5,704.0% and return on equity of -409.5%.
Valuation Metrics
Market Cap
$306.39M
Enterprise Value
$317.69M
P/E Ratio
-5.3x
PEG Ratio
0.0x
Price/Sales
148.7x
Growth & Margins
Revenue Growth (YoY)
-4.3%
Gross Margin
-311.7%
Operating Margin
-5,704.0%
Net Margin
-376.1%
EPS Growth
-4.3%
Financial Health
Cash/Price Ratio
+15.9%
Current Ratio
3.9x
Debt/Equity
572.1x
ROE
-409.5%
ROA
-51.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Humacyte, Inc. (HUMA) Business Model
About Humacyte, Inc.
What They Do
Develops bioengineered human tissues and organs.
Business Model
Humacyte generates revenue through the commercialization of its acellular tissue-engineered products, which are designed for a wide range of medical applications. The company offers innovative solutions for vascular repair and has a pipeline that includes advanced organ systems and tissue constructs for various medical needs, aiming to address significant healthcare challenges while minimizing the risk of immune rejection and infections.
Additional Information
Founded in 2004 and based in Durham, North Carolina, Humacyte specializes in regenerative medicine and tissue engineering. The company provides extensive support to healthcare professionals, including clinical education and operational training, to facilitate the use of its investigational products. Its expertise encompasses biomanufacturing scale-up and preclinical modeling, positioning it as a leader in the regenerative medicine sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
184
CEO
Dr. Laura E. Niklason M.D., Ph.D.
Country
United States
IPO Year
2020
Website
www.humacyte.comHumacyte, Inc. (HUMA) Latest News & Analysis
Latest News
Quick Summary
Shareholders can discuss their rights and options at no cost. Legal matters will be handled on a contingent fee basis, with no upfront payment required.
Why It Matters
Shareholder outreach indicates potential legal issues or disputes, which could affect stock performance and company reputation, impacting investor sentiment and stock valuation.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Analyst recommendations from brokerage firms can significantly impact stock prices, influencing investors' decisions to buy, sell, or hold stocks.
Why It Matters
Analyst recommendations can significantly sway stock prices, impacting investment decisions and market sentiment, thus affecting potential returns and portfolio strategy.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Humacyte presented research on its ATEV's self-repair capabilities after frequent dialysis cannulations. Top-line interim results from its Phase 3 study are expected in June 2026.
Why It Matters
Humacyte's promising data on its ATEV for dialysis access could enhance patient outcomes and market demand. Upcoming Phase 3 results may significantly impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Humacyte, Inc. announced that its Symvess surgical implant is now contracted with the U.S. VA's Strategic Acquisition Center, improving access to 170 VA hospitals.
Why It Matters
The contract enhances Symvess's market access to 170 VA hospitals, potentially boosting Humacyte's revenue and market presence, which could positively impact its stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Humacyte Q1 Earnings Call Highlights
27 days ago
Quick Summary
Humacyte (NASDAQ: HUMA) reported Q1 2026 sales of $0.5 million for Symvess and announced initiatives to boost adoption of its bioengineered vascular products.
Why It Matters
Humacyte's sales figures and strategic initiatives signal potential growth in the bioengineering sector, influencing investor sentiment and stock performance.
Source: MarketBeat
Market Sentiment:
Neutral
Quick Summary
Humacyte, Inc. appointed new executives and reported Q1 2026 sales of Symvess® at $0.5 million. They received a $1.475 million purchase commitment in Saudi Arabia and have pending U.S. Department of Defense funding.
Why It Matters
Leadership appointments signal strategic growth. Sales increase and international commitments indicate market potential. Upcoming clinical results could impact stock performance significantly.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About HUMA Stock
What is Humacyte, Inc.'s (HUMA) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Humacyte, Inc. (HUMA) has a median price target of $2.00. The highest price target is $3.00 and the lowest is $1.00.
Is HUMA stock a good investment in 2026?
According to current analyst ratings, HUMA has 4 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.38. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HUMA stock?
Wall Street analysts predict HUMA stock could reach $2.00 in the next 12 months. This represents a 44.9% increase from the current price of $1.38. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Humacyte, Inc.'s business model?
Humacyte generates revenue through the commercialization of its acellular tissue-engineered products, which are designed for a wide range of medical applications. The company offers innovative solutions for vascular repair and has a pipeline that includes advanced organ systems and tissue constructs for various medical needs, aiming to address significant healthcare challenges while minimizing the risk of immune rejection and infections.
What is the highest forecasted price for HUMA Humacyte, Inc.?
The highest price target for HUMA is $3.00 from Swayampakula Ramakanth at HC Wainwright & Co., which represents a 117.4% increase from the current price of $1.38.
What is the lowest forecasted price for HUMA Humacyte, Inc.?
The lowest price target for HUMA is $1.00 from at , which represents a -27.5% decrease from the current price of $1.38.
What is the overall HUMA consensus from analysts for Humacyte, Inc.?
The overall analyst consensus for HUMA is bullish. Out of 4 Wall Street analysts, 4 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $2.00.
How accurate are HUMA stock price projections?
Stock price projections, including those for Humacyte, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 9, 2026 2:57 AM UTC